Log in

CVE:AQS - Aequus Pharmaceuticals Stock Price, Forecast & News

+0.01 (+9.52 %)
(As of 02/23/2020 01:04 AM ET)
Today's Range
Now: C$0.12
50-Day Range
MA: C$0.12
52-Week Range
Now: C$0.12
Volume8,727 shs
Average Volume79,150 shs
Market CapitalizationC$9.25 million
P/E RatioN/A
Dividend YieldN/A
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Topiramate and Oxcarbazepine extended-release tablets for the treatment of epilepsy. Its development stage product candidates include AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and irritability associated with autistic disorders, as well as depressive disorders; AQS1303, a transdermal pyridoxine/ doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304 to treat neurological disorders. The company has a collaboration agreement with Scientus Pharma Inc. for the development and commercial supply of specific cannabinoid extracts; and licensing agreement with Supernus Pharmaceuticals, Inc. for the development and commercialization of products for the treatment of central nervous system disorders. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$1.33 million
Cash FlowC$0.01 per share
Book ValueC$0.00 per share



Market CapC$9.25 million
Next Earnings Date4/22/2020 (Estimated)
OptionableNot Optionable

Receive AQS News and Ratings via Email

Sign-up to receive the latest news and ratings for AQS and its competitors with MarketBeat's FREE daily newsletter.

Aequus Pharmaceuticals (CVE:AQS) Frequently Asked Questions

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How were Aequus Pharmaceuticals' earnings last quarter?

Aequus Pharmaceuticals Inc (CVE:AQS) announced its quarterly earnings results on Friday, November, 29th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.37 million during the quarter. View Aequus Pharmaceuticals' Earnings History.

When is Aequus Pharmaceuticals' next earnings date?

Aequus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Aequus Pharmaceuticals.

Has Aequus Pharmaceuticals been receiving favorable news coverage?

Media coverage about AQS stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aequus Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Aequus Pharmaceuticals.

Who are some of Aequus Pharmaceuticals' key competitors?

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include Growlife (PHOT), Terra Tech (TRTC), Supreme Cannabis (FIRE), LiCo Energy Metals (LIC), CROWN CASTLE IN/SH SH (CCI), Rogers (ROG), Acorn Energy (ACFN), Charlotte's Web (CWBHF), Marijuana Company Of America (MCOA) and Kintavar Exploration (KTR).

Who are Aequus Pharmaceuticals' key executives?

Aequus Pharmaceuticals' management team includes the folowing people:
  • Mr. Douglas Glen Janzen, Chairman, CEO & Pres (Age 50)
  • Ms. Ann Fehr CGA, CPA, Chief Financial Officer (Age 50)
  • Ms. Anne Michelle Stevens BSc, MHA, COO, Corp. Sec. & Director (Age 38)
  • Mr. Ian Richard Ball, Chief Commercial Officer
  • Dr. Donald Alan McAfee, Chief Scientific Officer (Age 77)

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.12.

How big of a company is Aequus Pharmaceuticals?

Aequus Pharmaceuticals has a market capitalization of C$9.25 million and generates C$1.33 million in revenue each year. Aequus Pharmaceuticals employs 10 workers across the globe.View Additional Information About Aequus Pharmaceuticals.

What is Aequus Pharmaceuticals' official website?

The official website for Aequus Pharmaceuticals is http://www.aequuspharma.ca/.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The company can be reached via phone at +1-604-3367906.

MarketBeat Community Rating for Aequus Pharmaceuticals (CVE AQS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Aequus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel